Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
NRAS Q61K
i
Other names:
NRAS1, HRAS1, N-Ras Protein Part 4, Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog, NRAS, Neuroblastoma RAS Viral Oncogene Homolog, NRAS Proto-Oncogene, GTPase
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4893
Related biomarkers:
Expression
Mutation
CNA
Others
‹
›
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
NRAS Q61K
Melanoma
NRAS Q61K
Melanoma
AZD5363
Sensitive: D – Preclinical
AACR 2023 - 2 weeks (New D)
AZD5363
Sensitive
:
D
AACR 2023 - 2wk
AZD5363
Sensitive: D – Preclinical
AACR 2023 - 2 weeks
AZD5363
Sensitive
:
D
AACR 2023 - 2 weeks - (New D)
NRAS Q61K
Melanoma
NRAS Q61K
Melanoma
trametinib + dabrafenib
Resistant: C3 – Early Trials
trametinib + dabrafenib
Resistant
:
C3
trametinib + dabrafenib
Resistant: C3 – Early Trials
trametinib + dabrafenib
Resistant
:
C3
NRAS Q61K
Hepatocellular Cancer
NRAS Q61K
Hepatocellular Cancer
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
sorafenib + BAY86-9766
Sensitive: C3 – Early Trials
sorafenib + BAY86-9766
Sensitive
:
C3
NRAS Q61K
Melanoma
NRAS Q61K
Melanoma
vemurafenib
Resistant: C3 – Early Trials
vemurafenib
Resistant
:
C3
vemurafenib
Resistant: C3 – Early Trials
vemurafenib
Resistant
:
C3
NRAS Q61K
Melanoma
NRAS Q61K
Melanoma
HL-085
Sensitive: C3 – Early Trials
HL-085
Sensitive
:
C3
HL-085
Sensitive: C3 – Early Trials
HL-085
Sensitive
:
C3
NRAS Q61K
Thyroid Gland Carcinoma
NRAS Q61K
Thyroid Gland Carcinoma
selumetinib
Sensitive: C3 – Early Trials
selumetinib
Sensitive
:
C3
selumetinib
Sensitive: C3 – Early Trials
selumetinib
Sensitive
:
C3
NRAS Q61K
Non Small Cell Lung Cancer
NRAS Q61K
Non Small Cell Lung Cancer
trametinib
Sensitive: C3 – Early Trials
trametinib
Sensitive
:
C3
trametinib
Sensitive: C3 – Early Trials
trametinib
Sensitive
:
C3
NRAS Q61K
Melanoma
NRAS Q61K
Melanoma
LY3009120
Sensitive: D – Preclinical
LY3009120
Sensitive
:
D
LY3009120
Sensitive: D – Preclinical
LY3009120
Sensitive
:
D
NRAS Q61K
Melanoma
NRAS Q61K
Melanoma
trametinib + palbociclib
Resistant: D – Preclinical
trametinib + palbociclib
Resistant
:
D
trametinib + palbociclib
Resistant: D – Preclinical
trametinib + palbociclib
Resistant
:
D
NRAS Q61K
Melanoma
NRAS Q61K
Melanoma
selumetinib
Sensitive: D – Preclinical
selumetinib
Sensitive
:
D
selumetinib
Sensitive: D – Preclinical
selumetinib
Sensitive
:
D
NRAS Q61K
Melanoma
NRAS Q61K
Melanoma
trametinib
Resistant: D – Preclinical
trametinib
Resistant
:
D
trametinib
Resistant: D – Preclinical
trametinib
Resistant
:
D
NRAS Q61K
Melanoma
NRAS Q61K
Melanoma
SBI-756
Sensitive: D – Preclinical
SBI-756
Sensitive
:
D
SBI-756
Sensitive: D – Preclinical
SBI-756
Sensitive
:
D
NRAS Q61K
Melanoma
NRAS Q61K
Melanoma
dabrafenib
Resistant: D – Preclinical
dabrafenib
Resistant
:
D
dabrafenib
Resistant: D – Preclinical
dabrafenib
Resistant
:
D
NRAS Q61K
Neuroblastoma
NRAS Q61K
Neuroblastoma
ASN007
Sensitive: D – Preclinical
ASN007
Sensitive
:
D
ASN007
Sensitive: D – Preclinical
ASN007
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login